Study M645
Study name | Milak MS 2020 |
Title | Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: a randomized clinical trial |
Overall design | The aim of this study was to evaluate whether ketamine dose and brain glutamate and glutamine (Glx) and GABA level responses to ketamine are related to antidepressant benefit and adverse effects. This randomized, parallel-group, triple-masked clinical trial included 38 physically healthy, psychotropic medication-free adult outpatients who were in a major depressive episode of MDD but not actively suicidal. Participants received 1 dose of placebo or ketamine (0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg) intravenously during 40 minutes of a proton magnetic resonance spectroscopy scan that measured ventro-medial prefrontal cortex Glx and GABA levels in 13-minute data frames. Metabolite quantification was reported relative to brain water concentration. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, MADRS >= 22 |
Sample size | 38 |
Tissue | Central; Brain; Ventro-medial prefrontal cortex; |
Platform | MRS; MRS: GE Signa EXCITE 3.0T MR scanner; |
PMID | |
DOI | |
Citation | Milak MS, Rashid R, Dong Z, et al. Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: a randomized clinical trial. JAMA Netw Open. 2020;3(8):e2013211. |
Metabolite |
